Dr. Evgenii Shumilov – Oncology and Hematology – Outstanding Scientist Award

Dr. Evgenii Shumilov - Oncology and Hematology - Outstanding Scientist Award

University Hospital Münster Medical Clinic A -  Germany

Author Profile 

ORCID 

🎓 Early academic pursuits

Dr. Evgenii Shumilov began his academic journey in kirovskaya gebiet, russland, where he completed his general secondary education in june 2006. driven by a passion for human biology and clinical care, he enrolled in the staatliche medizinische akademie in kirow in 2006. the following year, he transitioned to the esteemed st. petersburger staatliche medizinische universität i.p. pawlow, where he pursued his degree in human medicine until 2012. during this formative period, he developed a growing interest in the biochemical pathways influencing addiction, which would later shape his doctoral research.

🏥 Professional endeavors

His professional career started immediately after his graduation with a clinical internship in internal medicine at the universitätsklinikum st. petersburg i.p. pawlow. dr. shumilov then completed a specialized clinical training in oncology at the renowned n.n. petrow institute for oncology. from 2015 to 2021, he continued his facharztausbildung (specialist training) in internal medicine, hematology, and oncology at the universitätsmedizin göttingen. since 2021, he has served in various capacities at the universitätsklinikum münster, advancing to oberarzt (senior physician) in the day clinic of oncology by 2022. his role requires the coordination of clinical therapies, implementation of modern diagnostics, and integration of interdisciplinary care — akin to the precision and optimization seen in power electronics systems.

🔬 Contributions and research focus

Dr. Shumilov has made significant scientific contributions in the field of pharmacology and hemato-oncology. between 2012 and 2015, he pursued a doctoral program in pharmacology at the anichkow institute for experimental medicine, focusing on neuropharmacology and the role of orexin-1 receptors in addiction — a study that mirrors the regulatory mechanisms of feedback and control in power electronics. in 2018, he earned a second doctorate (dr. med.) from the university of bern, switzerland, with a dissertation exploring genetic mutations bridging Oncology and Hematology hematopoietic lineages and solid tumors in the age of high-throughput sequencing. his work has helped redefine diagnostic paradigms in clinical oncology.

🌍 Impact and influence

Dr. Shumilov’s cross-disciplinary expertise bridges clinical practice and molecular diagnostics. his innovative thinking, reflected in his dual doctoral research and international academic Oncology and Hematology exposure, positions him as a leader in precision medicine. like the transformative role of power electronics in renewable energy systems, his influence lies in optimizing diagnostic accuracy and tailoring therapies for oncology patients. he is actively mentoring junior clinicians, integrating translational research into routine care, and contributing to academic networks across europe and russia.

📚 Academic citations and recognitions

He has received notable academic recognition, including a posterpreis at the dgho annual meeting in stuttgart (2017), and the prestigious dfg “clinician scientist” funding from 2020 to 2021. his scientific contributions are frequently cited in studies on neuropharmacology and next-generation sequencing diagnostics. his work on orexin receptors and hematologic malignancies Oncology and Hematology continues to influence both pharmacologic models and clinical protocols.

🌱 Legacy and future contributions

Dr. Shumilov’s legacy lies in his capacity to interweave basic science with clinical oncology. he is currently leading projects that integrate high-throughput genomic data with patient-specific therapy plans, aiming for breakthroughs in hematologic and solid tumor treatments. with a forward-looking perspective, he is exploring digital integration and ai-assisted diagnostics, similar to how power electronics revolutionize control in automated systems. his future vision includes strengthening international research collaborations and expanding educational programs for medical scientists.

Notable Publications 

  • Title: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
    Author(s): Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo, Rebecca Wurm-Kuczera, Vladan Vucinic, Udo Holtick, Hristo Boyadzhiev, Thomas Melchardt, Alexander Sebastian Hölscher, et al.
    Journal: Blood Advances

  • Title: Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning
    Author(s): Evgenii Shumilov, Lena Levien, Paolo Mazzeo, Wolfram Jung, Andreas Leha, Raphael Koch, Justin Hasenkamp, Gerald Wulf
    Journal: Leukemia & Lymphoma

  • Title: Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study
    Author(s): Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, Meng Wang, Thomas Melchardt, Udo Holtick, Ulrike Bacher, Philipp B. Staber, Paolo Mazzeo, Corinna Leng, et al.
    Journal: Blood Advances

  • Title: Benefit of repeated COVID‐19 vaccination for patients with B‐cell malignancies
    Author(s): Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
    Journal: British Journal of Haematology

  • Title: Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era
    Author(s): Michael Oertel, Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, Anne Bremer, Stephan Rehn, Georg Lenz, Cyrus Khandanpour, Hans Theodor Eich
    Journal: Cancers

Assoc. Prof. Dr. Jun Xiu sheng – Cancer treatment – Best Researcher Award

Assoc. Prof. Dr. Jun Xiu sheng - Cancer treatment - Best Researcher Award

The First Affiliated Hospital of Dalian Medical University - China 

Author Profile 

SCOPUS 

ORCID 

🎓 Early academic pursuits

Jun Xiu sheng began his academic journey with a strong foundation in clinical medicine. from 2006 to 2011, he pursued a seven-year undergraduate program in clinical medicine at dalian medical university, followed by graduate studies from 2011 to 2013 at the same institution. in 2013, he embarked on a ph.d. in oncology at the graduate school of dalian medical university, sharpening his focus on cancer biology and therapy. his academic path was further enriched through a prestigious exchange scholar program at the medical university of wisconsin, usa, from 2015 to 2016, where he gained international exposure and research insight.

🩺 Professional endeavors

After completing his advanced education, jun xiu sheng joined the first affiliated hospital of dalian medical university. he served as a resident in the department of radiotherapy from 2016 to 2018 and quickly rose through the ranks to become an attending physician (2018–2020). since december 2020, he has held the position of deputy chief physician, where he also serves as an associate professor. his clinical expertise lies in radiation oncology, contributing to the development of novel therapeutic strategies in cancer care. jun xiu sheng’s interest in interdisciplinary approaches, including those inspired by power electronics systems, has made his clinical methods highly adaptive and innovative.

🔬 Contributions and research focus

With a ph.d. in oncology, jun xiu sheng has dedicated his research efforts to understanding the molecular and cellular mechanisms behind tumor resistance and radiotherapy. his recent work explores how melatonin modulates rna splicing in esophageal cancer cells, potentially increasing radiotherapy sensitivity. melatonin, known for its use in treating central nervous system Cancer treatment diseases, has shown promise in suppressing tumor growth. through bioinformatics and rna-seq analysis, jun xiu sheng has investigated the role of variable splicing in radiation resistance, aiming to unlock therapeutic pathways to improve cancer treatment outcomes. integrating ideas from power electronics systems, he also explores regulatory networks in tumor biology.

🌍 Impact and influence

Jun Xiu sheng’s research has not only advanced our understanding of cancer biology but also influenced therapeutic strategies in radiation oncology. by uncovering mechanisms related to rna Cancer treatment variable splicing and the effects of melatonin on tumor cells, he has provided critical insight into resistance pathways. his collaborative roles in national-level projects, including the national natural science foundation of china, have elevated his profile within the academic and medical communities. his interdisciplinary thinking, including applying models from power electronics, offers new paradigms in cancer signal processing and therapy modulation.

📚 Academic cites

Jun Xiu sheng has participated in several major research projects. he contributed to a study on circular rna generation funded by the national natural science foundation of china, and another Cancer treatment on the function of rna variable splicing in tumor radiotherapy resistance. as a principal investigator, he led projects on aspirin-induced rna splicing in lung cancer and on the immune regulation of head and neck squamous cell carcinoma (hnscc). his ongoing research into esophageal cancer immunotherapy and prognosis demonstrates a sustained commitment to scholarly contribution and scientific innovation.

🧬 Legacy and future contributions

Looking forward, jun xiu sheng is committed to deepening his exploration of tumor microenvironments, radiotherapy resistance mechanisms, and immune system interactions in cancer. his current projects funded by liaoning provincial programs and education departments reflect his active role in shaping the future of oncology. he envisions integrating computational and systemic models—akin to feedback loops found in power electronics—to decode complex biological responses in tumors. his legacy will be defined by a blend of rigorous scientific inquiry, clinical excellence, and forward-thinking applications in precision medicine.

Notable Publications 

Title: The role of oncostatin M in esophageal cancer and its potential as a prognostic marker
Author(s): Guangxiang Ding, Xianwei Li, Hongtao Yin, Bing Sun, Junxiu Sheng
Journal: Computers in Biology and Medicine, 2025

Dr. Melania Tesio – Oncologia –  Best Researcher Award

Dr. Melania Tesio - Oncologia -  Best Researcher Award

INSERM - France

Author Profile 

SCOPUS 

🎓 Early academic pursuits

Melania Tesio embarked on her academic journey with a solid foundation in medical biotechnology, earning her degree with full honors from the university of torino, italy, in 2002. her passion for oncology led her to pursue a doctoral degree, culminating in a ph.d. in human oncology in 2007. her studies were uniquely enriched by a dual affiliation with the university of torino and the weizmann institute of science, israel, where she collaborated on groundbreaking research projects that laid the groundwork for her future contributions to cancer research.

🧪 Professional endeavors

Following her ph.d., Melania transitioned into impactful research roles. from 2007 to 2008, she worked as a postdoctoral researcher at the weizmann institute of science under prof. tsvee lapidot, where she delved into hematopoietic and immune system dynamics. subsequently, she joined the german cancer research center (dkfz) in 2008, collaborating with prof. andreas trumpp until 2014. since 2017, she has been a researcher at inserm, contributing significantly to unit u1111, lyon, france, where she focuses on translational cancer research while balancing her roles during maternity leave and part-time work.

🔬 Contributions and research focus

Melania's research has consistently centered on understanding the molecular mechanisms underpinning cancer, particularly t-cell acute lymphoblastic leukemia (t-all). her studies have uncovered critical insights into metabolic rewiring induced by genetic abnormalities, such as pten loss. she has also contributed to elucidating Oncologia the molecular blueprints of thymopoiesis and enhancer activation in tcr development. her recent work as a senior researcher has focused on the intersection of metabolism and oncogenesis, driving innovative therapeutic strategies for blood cancers.

🏆 Accolades and recognition

Melania’s contributions have been widely recognized in the scientific community. with an h-index of 19 and over 2,800 citations, her work has significantly impacted Oncologia cancer biology. she has been the last and corresponding author on prestigious publications, showcasing her leadership in collaborative research. her groundbreaking findings have been published in high-impact journals like blood advances, leukemia, and j experimental medicine, further establishing her as a thought leader in oncology research.

🌟 Impact and influence

Through her pioneering research, melania has advanced the understanding of key biological pathways in leukemia, offering new avenues for therapeutic Oncologia interventions. her work on age-related clinical features of pten abnormalities in t-all and molecular mechanisms of tcr enhancer activation has provided valuable frameworks for clinical applications. as a mentor, she has inspired the next generation of researchers, fostering a culture of innovation and collaboration.

🌍 Legacy and future contributions

Melania’s legacy is deeply rooted in her commitment to translational oncology, where she bridges the gap between fundamental research and clinical applications. looking ahead, she aims to expand her research into metabolic dependencies in cancer, paving the way for precision medicine approaches. her dedication to unraveling complex biological systems continues to shape the field of cancer research, ensuring lasting contributions to scientific progress and patient care.

Notable Publications 

  • Title: Tell me who you go with and I'll tell you who you are
    Author: M. Tesio
    Journal: HemaSphere, 2024, 8(1), e36
  • Title: Editorial: Tyrosine kinases and phosphatases in T-cell malignancies
    Author: M. Tesio
    Journal: Frontiers in Oncology, 2024, 14, 1372133
  • Title: Sunscreen to Protect the Marrow
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(9), pp. E941
  • Title: Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(2), pp. E827
  • Title: Reporting From the First EHA Research Conference: Exciting Science With Panoramic Views
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(1), pp. E816